These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11361591)

  • 1. The role of the FDA in drug development: implications for improved access to new HIV/AIDS therapies. Testimony before the Subcommittee on Health and Environment-Committee on Commerce concerning FDA reform bill HR 3199.
    Cooper EC; Sanders S
    AIDS Patient Care STDS; 1996 Aug; 10(4):213-20. PubMed ID: 11361591
    [No Abstract]   [Full Text] [Related]  

  • 2. Who would approve new drugs if there were no FDA?
    Gatty B
    Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality assurance and the drug development process: an FDA perspective.
    Leonard EM
    Qual Assur; 1994 Jun; 3(2):178-86. PubMed ID: 7804633
    [No Abstract]   [Full Text] [Related]  

  • 4. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 7. The drive to reform the FDA gains momentum.
    Gatty B
    Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
    [No Abstract]   [Full Text] [Related]  

  • 8. It is time for food and drug administration reform.
    Guharoy R
    Arch Intern Med; 2010 Apr; 170(8):737. PubMed ID: 20421564
    [No Abstract]   [Full Text] [Related]  

  • 9. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should you let the FDA decide what drugs you pay for?
    Dutton G
    Bus Health; 1996 Oct; 14(10):65, 69-70, 73. PubMed ID: 10161492
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation.
    Kros JF; Keller CM
    Int J Electron Healthc; 2009; 5(2):164-76. PubMed ID: 19906632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internal reform at the FDA.
    Stein GC
    Am J Health Syst Pharm; 1996 Sep; 53(17):2087-9. PubMed ID: 8870898
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA appointee faces angry, demoralized staff.
    Fox JL
    Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
    [No Abstract]   [Full Text] [Related]  

  • 17. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 18. Reform at FDA: faster access to promising drugs? Food and Drug Administration.
    Baker R
    BETA; 1995 Jun; ():39-40. PubMed ID: 11362545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 20. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.